Moderna Drops, DoorDash Rises, Honeywell Plunges as Surprise Guidance Cut Alarms Wall Street
On this episode of Stock Movers:- Moderna (MRNA) shares drop. Moderna Inc. won US regulatory approval for a flu vaccine based on mRNA technology, called mFlusiva, for adults aged 50 and over. The immunization received a traditional approval for patients between the ages of 50 and 64, and an accelerated approval for those 65 and older. A post-marketing clinical trial will be required to confirm the vaccine’s benefit in people 65 and over, and supply is expected to be available in select retailers in the coming weeks. - DoorDash (DASH) shares rise. DoorDash issued a profit forecast that…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.